Ironjustic
Mon, May-14-07, 17:15
Study Demonstrating Aeolus Compound's Neuroprotection in
Parkinson's Disease Published in the Journal of
Neuroscience AEOL 11207, Administered Orally, Crossed the
Blood-Brain Barrier
First Demonstration of Neuroprotection by an Oral Catalytic
Antioxidant in the MPTP (Parkinson's) Mouse Model
LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus
Pharmaceuticals, Inc. (OTCBB:AOLS) announced today the
publication* in the April 18, 2007 issue of the Journal of
Neuroscience a study by researchers at the University of
Colorado and National Jewish Medical and Research Center
demonstrating that the Company's first orally available
catalytic antioxidant, AEOL 11207, demonstrated
neuroprotection in an animal model of Parkinson's disease
("PD"). The study also showed that the compound has favorable
blood-brain barrier permeability.
AEOL 11207 was tested for neuroprotection and oral
bio-availability in the mouse MPTP model of Parkinson's
disease. AEOL 11207 administered orally protected against
MPTP-induced dopamine depletion in the striatum as well as
dopaminergic neuronal loss, glutathione depletion, lipid
peroxidation, and 3-nitrotyrosine formation in the ventral
midbrain. Neuroprotection correlated with brain
metalloporphyrin concentrations. The researchers concluded
that AEOL 11207 demonstrated neuroprotection in the MPTP mouse
model and that the data support further investigation of AEOL
11207 as a potential treatment for PD and other
neuro-degenerative diseases.
The Potential for AEOL 11207 in Parkinson's and other
Neurodegenerative Diseases
A major hurdle to the treatment of chronic neurodegenerative
diseases is the development of efficacious and bioavailable
therapeutic agents that permeate the blood-brain barrier.
Catalytic removal of reactive species is a highly warranted,
yet novel approach for the treatment of age related
neurodegenerative diseases such as PD. The major therapeutic
approach currently used to alleviate the symptoms of PD
involves restoration of dopaminergic neurotransmission using
levodopa, dopamine agonists, and inhibitors of monoamine
metabolism. However, these therapeutic approaches are often
associated with serious adverse effects and fail to provide
long-term control of this inexorably progressive disease.
Therefore, there is an urgent need for novel classes of
therapeutic agents for the treatment of PD. This study
provides evidence that a novel lipophilic metalloporphyrin
penetrates the BBB following oral administration possesses a
long plasma and brain half-life and provides significant
neuroprotection by an antioxidant mechanism in a
well-established animal model of parkinsonism. This is the
first demonstration of protection by an orally active
metal-based catalytic antioxidant in the MPTP model.
About Aeolus Pharmaceuticals
Aeolus is developing a variety of therapeutic agents based on
its proprietary small molecule catalytic antioxidants, with
AEOL 10150 being the first to enter human clinical evaluation.
AEOL 10150 is a patented, small molecule catalytic antioxidant
that has shown the ability to scavenge a broad range of
reactive oxygen species, or free radicals. As a catalytic
antioxidant, AEOL 10150 mimics and thereby amplifies the
body's natural enzymatic systems for eliminating these
damaging compounds. Because oxygen-derived free radicals are
believed to have an important role in the pathogenesis of many
diseases, Aeolus' catalytic antioxidants are believed to have
a broad range of potential therapeutic uses. The Company
intends to develop, or partner for development, AEOL 10150 for
protection of healthy cells in cancer radiotherapy, and plans
to develop its first oral compound, AEOL 11207, for chronic
neurodegenerative diseases.
The statements in this press release that are not purely
statements of historical fact are forward-looking statements.
Such statements include, but are not limited to, those
relating to Aeolus' product candidates, as well as its
proprietary technologies and research programs. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Aeolus' actual
results to be materially different from historical results or
from any results expressed or implied by such forward-looking
statements. Important factors that could cause results to
differ include risks associated with uncertainties of
progress and timing of clinical trials, scientific research
and product development activities, difficulties or delays in
development, testing, obtaining regulatory approval, the need
to obtain funding for pre-clinical and clinical trials and
operations, the scope and validity of intellectual property
protection for Aeolus' product candidates, proprietary
technologies and their uses, and competition from other
biopharmaceutical companies. Certain of these factors and
others are more fully described in Aeolus' filings with the
Securities and Exchange Commission, including, but not
limited to, Aeolus' Quarterly Report on Form 10-Q for the
quarter ended December 31, 2006. Readers are cautioned not to
place undue reliance on these forward-looking statements,
which speak only as of the date hereof.
*Liang L-P, Huang J, Fulton R, Day BJ, Patel M. An Orally
Active Metalloporphyrin Protects against
1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine Neurotoxicity in
vivo. J. Neurosci. 27(16): 4326-4333, 2007
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
Parkinson's Disease Published in the Journal of
Neuroscience AEOL 11207, Administered Orally, Crossed the
Blood-Brain Barrier
First Demonstration of Neuroprotection by an Oral Catalytic
Antioxidant in the MPTP (Parkinson's) Mouse Model
LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus
Pharmaceuticals, Inc. (OTCBB:AOLS) announced today the
publication* in the April 18, 2007 issue of the Journal of
Neuroscience a study by researchers at the University of
Colorado and National Jewish Medical and Research Center
demonstrating that the Company's first orally available
catalytic antioxidant, AEOL 11207, demonstrated
neuroprotection in an animal model of Parkinson's disease
("PD"). The study also showed that the compound has favorable
blood-brain barrier permeability.
AEOL 11207 was tested for neuroprotection and oral
bio-availability in the mouse MPTP model of Parkinson's
disease. AEOL 11207 administered orally protected against
MPTP-induced dopamine depletion in the striatum as well as
dopaminergic neuronal loss, glutathione depletion, lipid
peroxidation, and 3-nitrotyrosine formation in the ventral
midbrain. Neuroprotection correlated with brain
metalloporphyrin concentrations. The researchers concluded
that AEOL 11207 demonstrated neuroprotection in the MPTP mouse
model and that the data support further investigation of AEOL
11207 as a potential treatment for PD and other
neuro-degenerative diseases.
The Potential for AEOL 11207 in Parkinson's and other
Neurodegenerative Diseases
A major hurdle to the treatment of chronic neurodegenerative
diseases is the development of efficacious and bioavailable
therapeutic agents that permeate the blood-brain barrier.
Catalytic removal of reactive species is a highly warranted,
yet novel approach for the treatment of age related
neurodegenerative diseases such as PD. The major therapeutic
approach currently used to alleviate the symptoms of PD
involves restoration of dopaminergic neurotransmission using
levodopa, dopamine agonists, and inhibitors of monoamine
metabolism. However, these therapeutic approaches are often
associated with serious adverse effects and fail to provide
long-term control of this inexorably progressive disease.
Therefore, there is an urgent need for novel classes of
therapeutic agents for the treatment of PD. This study
provides evidence that a novel lipophilic metalloporphyrin
penetrates the BBB following oral administration possesses a
long plasma and brain half-life and provides significant
neuroprotection by an antioxidant mechanism in a
well-established animal model of parkinsonism. This is the
first demonstration of protection by an orally active
metal-based catalytic antioxidant in the MPTP model.
About Aeolus Pharmaceuticals
Aeolus is developing a variety of therapeutic agents based on
its proprietary small molecule catalytic antioxidants, with
AEOL 10150 being the first to enter human clinical evaluation.
AEOL 10150 is a patented, small molecule catalytic antioxidant
that has shown the ability to scavenge a broad range of
reactive oxygen species, or free radicals. As a catalytic
antioxidant, AEOL 10150 mimics and thereby amplifies the
body's natural enzymatic systems for eliminating these
damaging compounds. Because oxygen-derived free radicals are
believed to have an important role in the pathogenesis of many
diseases, Aeolus' catalytic antioxidants are believed to have
a broad range of potential therapeutic uses. The Company
intends to develop, or partner for development, AEOL 10150 for
protection of healthy cells in cancer radiotherapy, and plans
to develop its first oral compound, AEOL 11207, for chronic
neurodegenerative diseases.
The statements in this press release that are not purely
statements of historical fact are forward-looking statements.
Such statements include, but are not limited to, those
relating to Aeolus' product candidates, as well as its
proprietary technologies and research programs. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Aeolus' actual
results to be materially different from historical results or
from any results expressed or implied by such forward-looking
statements. Important factors that could cause results to
differ include risks associated with uncertainties of
progress and timing of clinical trials, scientific research
and product development activities, difficulties or delays in
development, testing, obtaining regulatory approval, the need
to obtain funding for pre-clinical and clinical trials and
operations, the scope and validity of intellectual property
protection for Aeolus' product candidates, proprietary
technologies and their uses, and competition from other
biopharmaceutical companies. Certain of these factors and
others are more fully described in Aeolus' filings with the
Securities and Exchange Commission, including, but not
limited to, Aeolus' Quarterly Report on Form 10-Q for the
quarter ended December 31, 2006. Readers are cautioned not to
place undue reliance on these forward-looking statements,
which speak only as of the date hereof.
*Liang L-P, Huang J, Fulton R, Day BJ, Patel M. An Orally
Active Metalloporphyrin Protects against
1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine Neurotoxicity in
vivo. J. Neurosci. 27(16): 4326-4333, 2007
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk